|
Mr. Cleary is a prominent health care/biotech industry executive who brings to the company many years of successful and productive experience in both established and early stage companies. He has a history of providing consistent, rapid and extraordinary financial return to investors. His background also includes broad-based general management accomplishments, and a proven track record for building successful organizations. He is widely recognized as a seasoned leader, strong dealmaker and fundraiser in the industry.
Mr. Cleary recently completed a three-year association with Genteric, Inc. advancing its protein drug delivery technology platforms. Between 1999 and 2002 under his direction as President, CEO and a Director, the company raised $32 million in two venture investments and he developed Genteric into a leader in non-viral gene delivery.
Mr. Cleary was co founder, President and CEO of CardioGene Therapeutics, a leading cardiovascular gene therapy company, from its inception in 1996 until its successful merger with Boston Scientific Corporation in 1998. From 1993 to 1994, he was President, CEO and a Director of Theragen, a diversified gene therapy company, which he successfully merged, with GenVec, Inc. of Rockville, Maryland. From 1994 to 1996, he served as a member of the Board of Directors of GenVec, Inc. From 1986 to 1993, he was Group Vice President and Chief Financial Officer of Cytogen Corporation, a biotech company engaged in the development of cancer diagnostics and therapies using monoclonal antibodies.
Prior to joining Cytogen, Mr. Cleary held several senior management positions with Johnson & Johnson over a 14-year career. While serving as Vice President of Operations at J&J's medical device subsidiary Iolab Corporation between 1980 and 1986 the company enjoyed compound growth rates of 40% in sales and 50% in income on revenues in excess of $100 million. | 